A study evaluating cost-effectiveness and quality-adjusted life-year (QALY) of obinutuzumab chemotherapy followed by Obinutuzumab maintenance in public Chilean health system for the treatment advanced Non-Hodgkin Follicular Lymphoma
Latest Information Update: 22 May 2020
At a glance
- Drugs Obinutuzumab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
Most Recent Events
- 22 May 2020 New trial record
- 20 May 2020 Results presented at the 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research